Chris Hanson Founder and Chairman, Aromyx Board of Directors

Mr. Hanson has been involved with early-stage technologies for more than 20 years and has strong sales and management expertise. He founded Aromyx in April of 2006 to commercialize then-emerging technologies in the area of human olfaction. He has a successful background in getting research-stage technologies through productization and to market. Before Aromyx, he helped to start cognitive computing development at IBM. Mr. Hanson put together government research funding for the IBM Research program to reverse engineer the human brain and to mimic its synapses. He then led commercialization efforts for the new neurosynaptic 'brain' chip and software infrastructure. He has extensive experience starting new ventures. Mr. Hanson has led the creation of the Aromyx IP portfolio, which comprises some 29 issued U.S. and 49 issued foreign patents. Mr. Hanson also has a proven sales and sales management track record, in complex sales to large accounts. Mr. Hanson earlier worked for Seagate and two Silicon Valley startups, as well as for the National Security Agency and the U.S. Department of State. He was educated at Stanford University.

Ed Costello Vice President, Engineering

Mr. Costello has been bringing new technology to market, designing and implementing complex embedded and remote sensor systems in government and industry for over 20 years. While earning his Bachelor's Degree in Computer Science from Cal State Hayward, he designed software for commercial in-vivo radiation detection systems used to monitor employees at nuclear reactors and weapons plants. He worked at Lawrence Livermore National Laboratory (LLNL) for 14 years on advanced projects including image analysis for Nova Laser targets and high-speed laser control/monitoring systems. He designed and implemented the field sensor software for LLNL's Argus Security System - now the standard throughout the Department of Energy and Department of Defense complex. Mr. Costello has most recently consulted at Stanford Linear Accelerator Center and led software architecture and advanced application teams ranging from new technology startups to corporations including Palm, Leica Geosystems, Adobe Systems and Hewlett-Packard.

Todd Cushman Vice President, Marketing and Sales

Mr. Cushman has experience in sales and sales management in IT, data, software, hardware, services and pharma. He has also created three startups, and led development of e-commerce and computer security efforts at IBM Research. He has extensive M&A, business development and strategy experience.

Dr. Bill Harries Chief Scientist

Dr. Harries earned his Ph.D. in human anatomy and cell biology with a minor in biochemistry from Wayne State University School of Medicine. Dr. Harries has extensive graduate and undergraduate teaching experience and is a former assistant professor at the University of San Francisco. Dr. Harries determined the high resolution X-ray structure of the integral membrane protein, aquaporin 0 and has authored numerous peer-reviewed journal articles, review articles and book chapters on the membrane protein structure and function. Dr. Harries is currently the acting chief scientific officer and day to day manager of the Center for Structures of Membrane Proteins (CSMP), a specialized center of the National Institutes Of Health, National Institute of General Medical Sciences, Protein Structure Initiative at the University of California San Francisco. He is responsible for developing state of the art membrane protein expression, purification, crystallization, and structure determination methods and instrumentation.

Keith Milne CFO

Prior to Aromyx, Mr. Milne was CFO of f'Real! Foods, where he helped grow revenue 700% in nine years, maintaining profitability and leading to a successful exit. Mr. Milne brings 36 years of financial and risk management experience in early-stage growth companies, as well Fortune 500 corporations, to the Aromyx team. Mr. Milne has also been in CFO roles of nanotechnology company Nano-Tex and has extensive corporate experience as VP of Corporate Development at Kaiser Aluminum and Finance Director at Chevron Corporation and its subsidiaries, leading the $20 billion Tengiz Chevroil joint venture in Kazakhstan. Keith earned a B.S. in Biological Sciences from Stanford University, and an M.B.A. from the Stanford Graduate School of Business. He is also an Aromyx investor.

David Hartford Board Member

Mr. Hartford brings over 40 years of experience as a private equity investor, venture capitalist and entrepreneur to Aromyx. He has extensive experience in software and systems engineering, management and investing in the high tech world, and as a corporate and securities attorney. In 2006, Mr. Hartford was a Founding Partner at Aeris Capital where he managed global investments in private equity and venture funds, as well as in later stage technology companies. Beginning in 2016, Mr. Hartford transitioned to Senior Advisor at Aeris. Mr. Hartford served on the board of the European Venture Capital Association for four years. Mr. Hartford has a B.S. from the University of Pittsburgh; J.D. from the University of Pennsylvania and is a mentor at the Haas Graduate School of Business at UC Berkeley. He has also been an adjunct professor at Cal State University and in Moscow for the National Economy. David is a frequent speaker and contributor to industry conferences world-wide on private equity and technology topics.

Dr. Luke V. Schneider Board Member

Dr. Schneider is the founder and Chief Scientific Officer of Target Discovery, Inc. (TDI), a privately-held cancer diagnostics company. Prior to founding TDI, Dr. Schneider founded and served as the first Director of the Phosphor Diagnostics and Combinatorial Methods Centers at SRI International. He managed the Aerosol Drug Delivery Program at SRI, the birthplace of Inhale Therapeutics and Dura Pharmaceutical's Dry Powder Inhaler. While at SRI, Dr. Schneider led the team that won the first and was a member of the team that won the second Monsanto Million Dollar Challenges. Dr. Schneider also served as SRI's Director of Technology Development, helping to spin out Pangene, Facilichem, CombiCat, TagTech, and RepliScent. Dr. Schneider's own research interests over the last decade have been in systems biology modeling. He developed and validated the first mathematical models for histidine protein kinase regulatory systems in bacteria that explained how the response turned itself off. He also developed models for GPCR signal transduction, integral to the technology being developed by Aromyx. Dr. Schneider holds a Ph.D. and M.A. in Chemical Engineering from Princeton University, an M.S.E. and B.S.E.S. in Chemical Engineering, and a B.A. in Biology from the University of South Florida, has coauthored more than 15 papers and has 22 issued U.S. patents.